isis gathering momentum, page-57

The ISIS connection continues....

Extracts from source
Satellite Companies, Joint Ventures, and Out-licensed technology
ISIS utilizes its technology, IP, manufacturing, etc to form other partnerships that provide additional upside to shareholders at no or little cost.

Antisense Therapeutics Ltd (ASX: ANP))

public, ISIS owns 58.8m shares (<10%). Entire pipeline is generation 2.0 ISIS antisense molecules (see chart below).
10/2010: raised $2.4m in rights issue at $0.008 to fund ATL-1103, now 888m shares plus 120m new options. 3/31/11 has $2.5m cash on hand. 6/2011 raised A$0.5m (none to ISIS, 62.5m shares at A$0.008 plus 31.25m 18 month placement options at A$0.015 - Click for PR) to be used solely for ATL1103.
ISIS received $0.8m milestones in fy2010 (not sure what this was for, not mentioned in 2010 10k) 
Note: there is also an Antisense Pharma in Germany, appears to have no relation to ISIS (http://www.antisense-pharma.com/index_e.htm)
ATL1101 (target is IGF-1R): preclinical- select tox studies are done and now trying to partner for prostate cancer. 
9/2010: potential partner is evaluating drug in their animal models and hope they license. No mention in ISIS 2010 10k
ATL1102 (fka ISIS 107248, target is CD49d subunit of VLA-4, licensed from ISIS 12/2001-eligible for royalties and sublicense income): intended for multiple sclerosis, same target as tysabri and running trials the same way: 
6/2008: successful 8 wk p2a (reduced new active lesions)-
2/2008 partnered w/ Teva, but 3/2010 discontinued development. ISIS rec'd $1.4m sublicense fee 2008 and $2m for manufacturing in 2009.
9/2010 and 2010 10k: now seeking new partner for MS development. Also considering development of Inhaled formulation for asthma early stage (intend to outlicense, teva had and returned rights for this indication also).
9/2011: now applied for a patent for indication of "stem cell mobilization" to "enhance value to potential partners" (PR)
ATL1103 (target is Growth hormone receptor -expressed in liver and reduces serum IGF1): preclinical, jointly discovered in collaboration w/ ISIS (eligible for royalties and sublicense income) for growth disorders (acromegaly- orphan drug, $30k/yr/pt=close to $1b) and vision disorders (diabetic retinopathy-multiB mkt).  
Animal tox done (started 5/2008) and drug supply for p1 has been manufactured (10/2009 ISIS rec'd $0.65m payment in form of 18.5m shares). 8/2010: this is pgm the company is spending on. 1220/10: with new funds work on formulation for injection and submit clinical trial application for 2011 start.   6/2011: Received approval for and started 36 patient phase 1 trial in Australia, will complete single and multiple ascending dose portions 1q2012 (Click for PR w/ trial details). 9/2011: single dose stage complete with 24 patients (placebo,25,75,250,400 mg - no SAE), multidose (6x250 mg doses in 12 pts, follow for 35 days) is underway, will report data by yearend 2011 (Click for PR)
12/2010 rec'd new US patent thru 2025